SI-BONE, Inc. Receives FDA Clearance for New Implant System
SI-BONE, Inc. (Nasdaq: SIBN), a medical device company based in Silicon Valley, is focused on providing surgical solutions for sacropelvic disorders. The company has announced that it has received FDA 510(k) clearance for the iFuse TORQ TNT™ Implant System (TNT). This new implant system is tailored to address the unique anatomical and bone mineral density requirements of the sacrum and ilium, representing the next generation of technology for fixing pelvic fragility fractures and performing sacroiliac joint fusions.
Innovative Features of the TNT Implant System
The TNT system features a porous threaded implant designed to span the posterior pelvis, extending through the ipsilateral ilium, sacrum, and into the contralateral ilium (“through and through”). This cutting-edge design aims to enhance early fixation and minimize the risk of screw backout, facilitating quicker patient weight-bearing and mobilization.
Expert Opinions on the TNT Device
Dr. Charles Moon, Director of Orthopedic Trauma at Cedars-Sinai, notes that existing cannulated screws are outdated and were originally intended for hip fractures. The use of longer screws for pelvic fractures has led to considerable complications, particularly in elderly patients, including screw loosening and postoperative discomfort. With the launch of the TNT system, which is specifically crafted for sacropelvic anatomy, the likelihood of screw backout may be significantly reduced, potentially lowering the need for follow-up surgeries.
FDA Breakthrough Device Designation
The FDA has granted the TNT system the Breakthrough Device designation, acknowledging its potential to offer a more effective treatment for pelvic fragility fractures compared to traditional methods. Laura Francis, CEO of SI-BONE, emphasized the importance of this designation, as it underscores the company's dedication to developing solutions that meet essential clinical needs.
About SI-BONE, Inc.
SI-BONE (NASDAQ: SIBN) is a leading innovator in the surgical treatment of sacropelvic disorders. Since it pioneered minimally invasive surgery of the SI joint in 2009, the company has supported over 3,900 surgeons in conducting more than 100,000 sacropelvic procedures. SI-BONE has built a robust body of clinical evidence, including randomized controlled trials and numerous peer-reviewed publications, establishing itself at the forefront of surgical innovation.
Contact Information
For more information about SI-BONE and its products, please contact investor relations at Saqib Iqbal via email at investors@si-bone.com.
Frequently Asked Questions
What does the FDA clearance mean for SI-BONE, Inc.?
The FDA clearance allows SI-BONE to market the iFuse TORQ TNT Implant System, which enhances treatment options for patients with pelvic fractures.
How does the TNT implant system differ from previous devices?
The TNT system is specifically engineered for sacropelvic anatomy, utilizing a porous threaded structure that improves fixation and minimizes complications.
What is Breakthrough Device Designation?
This designation from the FDA indicates that a device has the potential to provide significant advantages over existing treatment options.
Who benefits from the new TNT system?
The primary beneficiaries are patients with pelvic fragility fractures, particularly the elderly, who will experience improved surgical outcomes and faster recovery times.
How many surgeons have used SI-BONE’s technologies?
More than 3,900 surgeons have employed SI-BONE’s surgical solutions, highlighting the company's strong influence in this medical specialty.
